# OnCo record fpi-2265 (drug). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)". Whole corpus: https://onco.cc/api/v1/onco.nt
@prefix schema: <https://schema.org/> .
@prefix onco: <https://onco.cc/ns#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://onco.cc/drugs/fpi-2265/>
  a schema:Drug ;
  onco:kind "drug" ;
  schema:identifier "fpi-2265" ;
  schema:name "FPI-2265"@en ;
  schema:alternateName "Ac225-PSMA I&T"@en ;
  schema:description "FPI-2265 is an experimental radioligand therapy from Fusion Pharmaceuticals in phase 2 trials for prostate cancer, aimed at PSMA."@en ;
  schema:url <https://onco.cc/drugs/fpi-2265/> ;
  schema:dateModified "2026-09-11"^^xsd:date ;
  schema:citation <https://clinicaltrials.gov/search?intr=FPI-2265> ;
  onco:status "phase-2" ;
  onco:tag "pipeline", "ctgov-ingest" ;
  onco:modality "radioligand" ;
  onco:cancers <https://onco.cc/cancers/prostate/> ;
  onco:targets <https://onco.cc/targets/psma/> ;
  onco:companies <https://onco.cc/companies/astrazeneca/> ;
  onco:trials <https://onco.cc/trials/nct07611110/>, <https://onco.cc/trials/nct05219500/>, <https://onco.cc/trials/nct07590934/>, <https://onco.cc/trials/nct06909825/> .